Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings in Brief: Photoelectron

This article was originally published in The Gray Sheet

Executive Summary

Photoelectron: Net proceeds from the firm's IPO reach $17.2 mil. following purchase of 275,000 over-allotment shares. The Lexington, Massachusetts company went public January 29 via an initial offering of 2 mil. shares at $8.50 per share. About 6.8 mil. shares are now outstanding. A preliminary prospectus had called for an offering price of $11-13 per share ("The Gray Sheet" Nov. 11, p. 25). A portion of proceeds from the offering will be used to expand clinical trials and seek regulatory approval for the firm's Photon Radiosurgery System for radiation treatment of cancerous tumors ("The Gray Sheet" Feb. 19, 1996, I&W-10). Funds also will go toward increased R&D, expanded manufacturing and marketing, working capital and general corporate purposes. Needham & Company and Dain Bosworth were underwriters for the offering...
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT007791

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel